TG Therapeutics, Inc. (TGTX)
NasdaqCM · USD · Healthcare · Biotechnology
$55.15 (+0.66%) as of
Key statistics
- Market cap
- 8.44B
- P/E (TTM)
- 20.05
- Forward P/E
- 20.37
- EPS (TTM)
- 2.75
- Dividend yield
- 0.00%
- 52-week range
- 26.76 – 59.30
- Beta
- 1.80
- Revenue (TTM)
- 799.54M
- Profit margin
- 55.22%
- Analyst target
- $69.71
- Volume
- 107.00k
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Morrisville, NC, United States
- Employees
- 399
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.